GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Silence Therapeutics
Silence Therapeutics is a biotech company specializing in RNA interference. Its stock price is driven by news of clinical trials and partnerships with major pharmaceutical companies. The price chart is a bet on the success of its scientific platform.
Share prices of companies in the market segment - Dna
Silence Therapeutics is a biotech company that uses RNA interference (RNAi) technology to "silence" disease-causing genes. We've categorized it as "DNA," and the chart below shows how the market is assessing the prospects for this breakthrough in genetic medicine.
Broad Market Index - GURU.Markets
Silence Therapeutics is a biotech company that uses RNA interference (RNAi) technology to "silence" disease-causing genes. We've categorized it as "DNA," and the chart below shows how the market is assessing the prospects for this breakthrough in genetic medicine.
Change in the price of a company, segment, and market as a whole per day
SLN - Daily change in the company's share price Silence Therapeutics
Shares of Silence Therapeutics, a pioneer in RNA therapy, are exhibiting the extreme volatility typical of biotech. change_co tracks investor reactions to the publication of research data. This parameter is key for building high-risk asset valuation models on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Dna
Silence Therapeutics plc is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with the performance of SLN, a pioneer in RNA interference, helps to assess it as a high-risk, clinical-data-dependent asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Silence is a biopharmaceutical company, a leader in RNA interference (RNAi), a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Silence's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Silence Therapeutics
For Silence Therapeutics, the year-over-year trend is a story of gene silencing (siRNA) drug development. Its 12-month market cap depends on progress in clinical trials and partnerships with major pharmaceutical companies like AstraZeneca, which confirm the potential of its platform for targeted drug development.
Annual dynamics of market capitalization of the market segment - Dna
Silence Therapeutics plc is a biotech company pioneering the development of RNA interference (RNAi) therapeutics. Its stock performance depends on the success of its scientific platform and partnerships with major pharmaceutical companies. The chart reflects the high potential and risks of this cutting-edge field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Silence Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its share price (ADR) reflects investor hopes for the success of its RNA platform trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Silence Therapeutics
Silence, a biopharmaceutical company, is driven by its scientific platform. The monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its RNAi-based drugs and partnerships with major pharmaceutical companies.
Monthly dynamics of market capitalization of the market segment - Dna
Silence Therapeutics is a biotech company that uses RNA interference (RNAi) technology to "knock out" disease-causing genes. It targets rare blood and heart diseases. The chart below reflects the mood in the cutting-edge genetic engineering sector, where Silence is a key player.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Silence Therapeutics plc is a biotech company developing RNA interference-based drugs. Its shares are a bet on the success of its scientific platform. Their performance is entirely dependent on the results of clinical trials and partnerships and has no correlation to the market, making them a high-risk investment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Silence Therapeutics
Shares of Silence Therapeutics, a company developing RNA interference drugs, are extremely volatile. Weekly price movements depend entirely on clinical trial results and news of partnerships with major pharmaceutical companies. The chart below illustrates how short-term scientific events influence stock prices in cutting-edge biotech companies.
Weekly dynamics of market capitalization of the market segment - Dna
How unique is Silence Therapeutics's performance in the biotech sector? This chart compares the weekly price movements of this RNA therapy company with the overall trend. This helps us understand whether its sharp movements are a unique reaction to news in this cutting-edge field or reflect broader sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Silence Therapeutics is developing a new class of drugs based on RNA interference. It's a breakthrough, but risky technology. This chart compares its volatile weekly performance with the market, showing how its shares move based on news about scientific breakthroughs, completely ignoring overall market trends.
Market capitalization of the company, segment and market as a whole
SLN - Market capitalization of the company Silence Therapeutics
The Silence Therapeutics market cap chart represents the valuation of its gene silencing platform using small interfering RNA (siRNA). The company's market cap depends on the success of its clinical programs for treating rare diseases. The price trend shows how investors view the potential of this cutting-edge genetic technology.
SLN - Share of the company's market capitalization Silence Therapeutics within the market segment - Dna
Silence Therapeutics plc is a leader in the development of RNA interference (RNAi) therapies. Its market share is based on its siRNA platform, which enables the "silencing" of disease-causing genes, with a focus on cardiovascular disease.
Market capitalization of the market segment - Dna
This chart is a barometer of the revolutionary RNA interference (RNAi) technology. Silence Therapeutics is one of the European leaders in this field. The dynamics on the chart reflect the scientific breakthroughs and partnerships with major pharma that are driving this new class of drugs forward.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart represents the market valuation of cutting-edge gene silencing technology. Silence Therapeutics' market cap is based on its RNA interference platform for treating rare diseases. The line shows how fundamental science capable of "silencing" diseases at the genetic level shapes its value in global medicine.
Book value capitalization of the company, segment and market as a whole
SLN - Book value capitalization of the company Silence Therapeutics
Silence Therapeutics' book value represents its scientific capital. The chart below reflects the valuation of its unique mRNA interference platform (mRNAi GOLD™) for developing drugs that "turn off" disease-causing genes. The pipeline's growth signals advances in research, which is the biotech company's core asset.
SLN - Share of the company's book capitalization Silence Therapeutics within the market segment - Dna
For Silence Therapeutics, which specializes in RNA interference, its tangible assets are cutting-edge laboratories and scientific equipment, not factories. The chart shows its share of this unique scientific infrastructure, which forms the physical basis for the creation of a new class of drugs.
Market segment balance sheet capitalization - Dna
Below you can see the overall book value of the pharmaceutical sector. Against this backdrop, Silence Therapeutics, as a pioneer in RNA interference, looks like a lightweight. Its value lies in its unique scientific platform and patents, not in the manufacturing capabilities it can outsource to partners.
Book value of all companies included in the broad market index - GURU.Markets
Silence Therapeutics develops RNA interference-based drugs that "switch off" disease-causing genes. The company's assets are their scientific platform and development pipeline. Their balance sheet represents the value of a "molecular switch" for disease. Against the backdrop of the material world, they create a tool for fine-tuning it.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Silence Therapeutics
Silence Therapeutics' balance sheet is made up of its cash and RNAi platform. Its market capitalization is a measure of its partnerships with major pharma and the potential of its developments. The MvsBCap_Co chart shows the premium the market is paying for gene silencing technology and the trust of industry giants.
Market to book capitalization ratio in a market segment - Dna
Silence Therapeutics is a biotech company specializing in RNA interference (RNAi) to "silence" disease-causing genes. Its value lies in its scientific platform. The chart shows the high market appreciation for its technology and partnerships with major pharmaceutical companies.
Market to book capitalization ratio for the market as a whole
Silence Therapeutics is a biotech company specializing in the development of RNA interference (RNAi)-based drugs that can "switch off" disease-causing genes. The company's value lies in its scientific platform. This chart illustrates why investors are willing to pay a premium for innovative approaches to drug development.
Debts of the company, segment and market as a whole
SLN - Company debts Silence Therapeutics
Silence Therapeutics, a company developing RNA interference drugs, uses debt to finance its research platform. This chart shows how the company raises capital to conduct clinical trials for treatments for rare diseases. In this cutting-edge field of genetics, debt is an investment in the development of a new class of drugs.
Market segment debts - Dna
Silence Therapeutics is a biotech company specializing in RNA interference (RNAi), a technology that allows for the "silencing" of disease-causing genes. This is a cutting-edge field in medicine. This chart shows how the company funds its expensive research and development efforts in the clinical stage.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Silence Therapeutics
Silence Therapeutics is a biotech company specializing in RNA interference. This chart shows how reliant it is on debt to finance its research. For a company working at the forefront of genetics, debt is both an opportunity to accelerate research and a huge risk if it doesn't lead to a commercial product.
Market segment debt to market segment book capitalization - Dna
Silence Therapeutics is a biotech company specializing in the development of RNA interference (RNAi) drugs for the treatment of rare diseases. This is a cutting-edge, but expensive, technology. The chart shows how the company's debt load for R&D funding compares to the market capitalization of the entire biotech sector.
Debt to book value of all companies in the market
Silence Therapeutics (SLN) is developing a new class of RNA interference (RNAi)-based drugs for the treatment of rare diseases. This is a high-tech and risky area of biotech. This chart shows the overall debt burden of the economy. It helps explain why companies like SLN finance their time-consuming and expensive research solely with equity capital.
P/E of the company, segment and market as a whole
P/E - Silence Therapeutics
This chart for Silence Therapeutics, a company developing drugs based on RNA interference technology, is a measure of its belief in its scientific platform. There is no P/E ratio. The valuation is based on the potential of its drugs to treat rare diseases and partnerships with major pharmaceutical companies that validate the value of its technology.
P/E of the market segment - Dna
This industry metric represents the average P/E for biotech companies. For Silence Therapeutics, which works in RNA therapeutics, it serves as a benchmark. It reflects the overall level of investor confidence in this cutting-edge technology, providing context for Silence's valuation, which is a bet on its scientific platform.
P/E of the market as a whole
Silence Therapeutics is a biotech company pioneering the development of RNA interference (RNAi)-based drugs. This technology allows for the "silencing" of genes responsible for disease. This risk appetite chart helps understand how investors value companies at the forefront of genetic medicine.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Silence Therapeutics
Silence Therapeutics is a biotechnology company specializing in drug development using RNA interference (RNAi) technology, which enables the "silencing" of disease-causing genes. This graph reflects the expectations for this cutting-edge platform. The valuation is dependent on the success of its clinical programs and partnerships with major pharmaceutical companies.
%20P%2FE%20Silence%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Silence-Therapeutics&v=1772647839176 "Chart of the company's future (projected) P/E Silence Therapeutics")
Future (projected) P/E of the market segment - Dna
Silence Therapeutics develops drugs based on RNA interference (siRNA) technology to treat rare diseases. This chart reflects the company's long-term profitability expectations. It shows how highly the market values their scientific platform and partnerships with major pharmaceutical companies to bring new drugs to market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772647839256 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Silence Therapeutics is a company developing RNA interference (RNAi)-based drugs that silence disease-causing genes. This cutting-edge technology is at the forefront of research. This market expectations chart reflects investor willingness to fund breakthrough biotech platforms. Market optimism makes it easier for such companies to raise capital.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772647839402 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Silence Therapeutics
Silence Therapeutics is a biotechnology company specializing in RNA interference (RNAi), a technology that enables the "silencing" of disease-causing genes. The company develops drugs for the treatment of rare diseases. Its financial results reflect the costs of clinical trials of this cutting-edge platform.
Profit of companies in the market segment - Dna
Silence Therapeutics develops drugs using RNA interference technology to "switch off" disease-causing genes. The company has partnerships with major pharmaceutical companies. This chart illustrates how biotech platforms can generate revenue through collaborations long before their own product launches, impacting the overall profitability of the R&D sector.
Overall market profit
Silence Therapeutics is a biotech company developing drugs using RNA interference technology, a cutting-edge scientific approach to "silencing" disease-causing genes. The company's success depends on clinical data and partnerships with major pharmaceutical companies, not on the macroeconomic situation reflected in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Silence Therapeutics
Silence Therapeutics is a leader in developing RNA interference (RNAi)-based drugs targeting the genetic causes of disease. This timeline reflects expectations, which depend on the success of its platform and clinical development. Partnerships with major pharmaceutical companies are also an important source of revenue and technology validation.
%20profit%20of%20the%20company%20Silence%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Silence-Therapeutics&v=1772647840040 "Graph of future (projected) profit of the company Silence Therapeutics")
Future (predicted) profit of companies in the market segment - Dna
Silence Therapeutics specializes in developing RNA interference (RNAi) therapeutics for rare diseases. This chart shows the revenue forecast for the entire DNA and RNA therapeutics industry. It reflects expectations for the adoption of this new class of drugs. This background is important for assessing the scientific progress and commercial potential of Silence's siRNA platform.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772647840118 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Silence Therapeutics is a company developing drugs based on RNA interference technology. Its success depends on the results of clinical trials and partnerships with major pharmaceutical companies. The overall investment climate, which can be assessed using this chart, determines the availability of funding and the willingness of "big pharma" to invest in new technologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772647840264 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Silence Therapeutics
Silence Therapeutics is a biotech company specializing in the development of RNA interference (RNAi)-based drugs that can "switch off" disease-causing genes. This chart shows how investors view its scientific platform and partnerships with major pharmaceutical companies to develop a new class of precision medicines.
P/S market segment - Dna
Silence Therapeutics is a biotech company specializing in the development of a new class of RNA interference (RNAi)-based drugs to suppress disease-causing genes. The company focuses on rare diseases. This chart shows the average valuation in the sector, which helps understand the market premium placed on Silence Therapeutics' innovative scientific platform.
P/S of the market as a whole
Silence Therapeutics is a biotech company specializing in the development of RNA interference (RNAi)-based drugs that can "switch off" disease-causing genes. This cutting-edge technology has broad potential. This market valuation chart helps understand the premium investors are paying for this potentially revolutionary, yet risky, revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Silence Therapeutics
Silence Therapeutics is a biotech company specializing in RNA interference (RNAi) to "silence" disease-causing genes. Its valuation is based on future potential. This chart reflects investors' confidence in its technology platform and ability to develop commercially viable drugs.
%20P%2FS%20Silence%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Silence-Therapeutics&v=1772647840519 "The graph of the company's future (projected) P/S Silence Therapeutics")
Future (projected) P/S of the market segment - Dna
Silence Therapeutics is a biotech company leading the development of RNA interference therapeutics for disease treatment. This chart compares market expectations for its future revenue with other companies in the DNA technology sector. This valuation reflects investor confidence in its siRNA platform and its partnerships with major pharmaceutical companies.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772647840536 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Silence Therapeutics develops drugs using RNA interference technology, which "switches off" disease-causing genes. This is at the forefront of genetics. Market optimism, as seen in this chart, is vital for the company, as it provides access to the capital needed to conduct lengthy and expensive clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772647840566 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Silence Therapeutics
Silence Therapeutics is a biotechnology company specializing in the development of RNA interference (RNAi) drugs for the treatment of rare diseases. Its revenue comes from upfront and milestone payments from large pharmaceutical partners who license its technology platform. The chart shows the cash flows from these strategic alliances.
Sales of companies in the market segment - Dna
Silence Therapeutics is a biotech company leading the development of a new class of RNA interference (RNAi)-based drugs. Its platform enables the "silencing" of genes responsible for disease development. Revenue is generated through partnerships with major pharmaceutical companies. This chart shows the potential of RNA therapy, which is becoming one of the most promising areas in medicine.
Overall market sales
Silence Therapeutics is a company developing drugs using RNA interference technology. This is a cutting-edge scientific field, and the company's success depends on clinical results. This timeline is important indirectly, as it impacts the overall investment environment and the ability of biotech companies to raise capital for expensive research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Silence Therapeutics
Silence Therapeutics is a biotechnology company specializing in the development of RNA interference (RNAi) therapies for the treatment of rare diseases. This technology enables the "silencing" of disease-causing genes. This chart reflects analyst expectations for the success of the company's clinical programs and the commercial potential of its RNAi therapies.
%20sales%20of%20the%20company%20Silence%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Silence-Therapeutics&v=1772647840983 "Schedule of future (projected) sales of the company Silence Therapeutics")
Future (projected) sales of companies in the market segment - Dna
Silence Therapeutics specializes in developing drugs based on RNA interference (siRNA) technology for the treatment of rare diseases. This chart shows the overall outlook for the DNA and RNA therapeutics sector. It allows one to assess the competitiveness of the company's platform and how its partnerships with major pharmaceutical companies are impacting its development.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772647841034 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Silence Therapeutics is a company specializing in the development of RNA interference (RNAi) drugs for the treatment of diseases. This chart, reflecting its biotechnology investments, is important for the company. Developing such cutting-edge technology requires significant capital, and overall economic confidence influences investors' willingness to fund long-term scientific projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772647841109 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Silence Therapeutics
Silence Therapeutics is a biotech company developing a new class of RNA interference (RNAi)-based drugs for the treatment of genetic diseases. Its business is driven by cutting-edge science, requiring partnerships and investment. This chart shows the company's financial trajectory as it seeks to transform its unique scientific platform into commercial drugs.
Market segment marginality - Dna
Silence Therapeutics is a biotech company pioneering the field of RNA interference (RNAi). Their platform allows them to "turn off" genes responsible for disease development. This chart reflects their investment in this cutting-edge science, which has the potential to create a new class of highly profitable drugs.
Market marginality as a whole
Silence Therapeutics is a company specializing in the development of RNA interference (RNAi) drugs for the treatment of rare diseases. The overall picture of profitability is irrelevant for them. Their value lies in their scientific platform. Success depends on the results of clinical trials and partnerships with major pharmaceutical companies to bring their innovative drugs to market.
Employees in the company, segment and market as a whole
Number of employees in the company Silence Therapeutics
Silence Therapeutics is a biotech company pioneering RNA interference for disease treatment. This graph shows the team of scientists working on this cutting-edge platform. The growth in staff reflects progress in clinical programs and partnerships with major pharmaceutical companies.
Share of the company's employees Silence Therapeutics within the market segment - Dna
Silence Therapeutics is a leader in developing RNA interference (RNAi)-based drugs for diseases with high unmet needs. This chart shows the percentage of leading scientists in this cutting-edge field of genetics that the company attracts. This is a testament to its scientific expertise and the team creating the next generation of targeted therapies.
Number of employees in the market segment - Dna
Silence Therapeutics is a biotech company specializing in RNA interference (RNAi) drug development. This chart shows the growth of employment in this cutting-edge biotech field. The increase in scientists reflects progress in developing this platform for silencing disease-causing genes, opening new horizons in the treatment of rare and common diseases.
Number of employees in the market as a whole
Silence Therapeutics is a biotech company specializing in the development of RNA interference (RNAi) drugs that can "switch off" disease-causing genes. This is cutting-edge genetic medicine. This graph shows the overall labor market, where companies like Silence are creating high-tech jobs for scientists working on therapies of the future.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Silence Therapeutics (SLN)
Silence Therapeutics plc is a biotech company specializing in RNA interference. Its value lies in the potential of its scientific platform. This chart clearly demonstrates a business built on intellectual capital. A small team of scientists can create technology worth billions of dollars, resulting in an extremely high market capitalization per employee.
%20of%20the%20company%20Silence%20Therapeutics%20(SLN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Silence-Therapeutics-SLN&v=1772647841608 "Chart of market capitalization per employee (in thousands of dollars) of the company Silence Therapeutics (SLN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Silence Therapeutics develops RNA interference (RNAi)-based drugs to "switch off" disease-causing genes. This cutting-edge technology is at the forefront of research. The chart shows how highly the market values the company's intellectual capital. The per-employee value reflects investors' confidence in the potential of its platform to create breakthrough drugs.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772647841625 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Silence Therapeutics is a company developing drugs based on RNA interference (siRNA) technology, which "silences" disease-causing genes. This chart shows a high market value per employee, reflecting the value of their cutting-edge scientific platform and partnerships with major pharmaceutical companies.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772647841720 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Silence Therapeutics (SLN)
Silence Therapeutics (SLN) is a biotech company developing RNA interference (RNAi) therapies. This is cutting-edge R&D. This chart shows the "cost of science"—the negative profit (expense) per scientist working on their siRNA platform, which silences disease-causing genes.
%20Chart%20Silence%20Therapeutics%20(SLN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Silence-Therapeutics-SLN&v=1772647841739 "Company Profit Per Employee (in thousands of dollars) Chart Silence Therapeutics (SLN)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Silence Therapeutics develops RNA interference (RNAi)-based drugs. Their "GalNAc" platform enables the "silencing" of disease-causing genes. This graph demonstrates the benchmark for biotech staff efficiency. It is important for assessing how effectively Silence's scientific team is using its platform to create future drugs.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772647841784 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Silence Therapeutics is a biotech company specializing in RNA interference (siRNA) to "silence" disease-causing genes. It's a complex R&D platform. This chart shows the investment per scientist. Profits are not generated here, but rather spent in the hopes of developing patents and drugs that will then generate revenue through partnerships or sales.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772647841866 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Silence Therapeutics (SLN)
Silence Therapeutics is a biotech company specializing in the development of RNA interference (RNAi) drugs for the treatment of rare diseases. This chart reflects its scientific focus. Revenue per employee, if any, is likely from partnerships, as the team's primary focus is clinical research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Silence-Therapeutics-SLN&v=1772647841921 "Sales chart per company employee Silence Therapeutics (SLN)")
Sales per employee in the market segment - Dna
Silence Therapeutics (SLN) is a biotech company specializing in the development of RNA interference (RNAi)-based drugs to silence disease-causing genes. This graph shows the revenue (from partnerships) generated by each employee (scientist). It's an indicator of the productivity of their gene therapy R&D platform.
Sales per employee for the market as a whole
Silence Therapeutics is a biotech company specializing in gene silencing (RNAi) technology. It's an R&D platform. This chart illustrates their model: the company generates revenue not from sales, but through partnerships with large pharmaceutical companies (like AstraZeneca), which pay large upfront and milestone payments for access to their technology.
Short shares by company, segment and market as a whole
Shares shorted by company Silence Therapeutics (SLN)
Silence Therapeutics is a biotech company specializing in gene silencing (RNAi) technology for the treatment of various diseases. This chart shows bearish bets. The short position is driven by the company's competitive position (versus Alnylam) and the need to prove that its platform can create successful and safe drugs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Silence-Therapeutics-SLN&v=1772647842048 "Short Shares Chart for the Company Silence Therapeutics (SLN)")
Shares shorted by market segment - Dna
Silence Therapeutics (SLN) is a biotech company developing RNA interference (RNAi) drugs for rare diseases (such as hematological diseases). This chart is a barometer of sentiment across the entire biotech industry. If investors are shorting the sector, they don't believe risky R&D will succeed. For Silence, which relies on capital, this signals a "venture drought" for funding trials.
Shares shorted by the overall market
Silence Therapeutics (SLN) is a biotech company developing a new generation of RNA interference (RNAi)-based drugs. This is complex and risky science. This market pessimism chart shows when investors are risk-averse. SLN shares, dependent on R&D success, suffer greatly at such times.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Silence Therapeutics (SLN)
Silence Therapeutics develops RNA interference (RNAi) therapies. The stock is speculative and dependent on R&D. This chart can surge above 70 on positive trial data or partnerships, indicating euphoria. Oversold territory (<30) often reflects setbacks, delays, or funding concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Silence-Therapeutics-SLN&v=1772647842342 "RSI 14 indicator chart for the company's stock Silence Therapeutics (SLN)")
RSI 14 Market Segment - Dna
Silence Therapeutics is a biotech company developing RNA interference (siRNA)-based drugs. This technology allows for the "silencing" of genes that cause rare diseases. This graph measures the collective momentum in the gene and RNA therapy sector. It helps distinguish the reaction to SLN's clinical data from the general "emotional" wave across the biotech industry.
RSI 14 for the overall market
Silence Therapeutics (SLN) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SLN (Silence Therapeutics)
Silence Therapeutics is a biotech company specializing in RNA interference (RNAi). Its platform (GalNAc) allows for the "silencing" of disease-causing genes. This chart shows the average target price. Analysts' forecasts are based on clinical data and the value of partnerships (such as with AstraZeneca) for this platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SLN-Silence-Therapeutics&v=1772647842451 "A chart showing analyst consensus forecasts for the expected stock price. SLN (Silence Therapeutics)")
The difference between the consensus estimate and the actual stock price SLN (Silence Therapeutics)
Silence Therapeutics (SLN) is a biotech company using a cutting-edge RNAi (RNA interference) platform to knock out disease-causing genes, with a focus on rare diseases. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SLN-Silence-Therapeutics&v=1772647842482 "A chart showing the difference between the consensus forecast and the actual stock price. SLN (Silence Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Dna
Silence Therapeutics (SLN) is a biotech company developing RNA interference (RNAi) drugs—a technology for "silencing" disease-causing genes. This chart shows general expectations for the DNA technology sector, reflecting whether experts believe this cutting-edge platform will be commercially successful.
Analysts' consensus forecast for the overall market share price
Silence Therapeutics is a biotech company specializing in RNA interference (RNAi), which "turns off" genes that cause rare blood and cardiovascular diseases. This chart shows the overall "risk appetite." For Silence, which operates at the forefront of science, overall market optimism (a rising chart) is critical to attracting the capital needed to fund expensive R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Silence Therapeutics
Silence Therapeutics (SLN) is a biotech company working in the cutting-edge field of gene silencing. Their RNAi platform creates drugs that silence genes that cause rare diseases. This chart is a clear indicator of faith in their R&D platform. It reflects their progress in clinical trials and their partnerships with major pharma, which licenses their technology.
AKIMA Market Segment Index - Dna
Silence Therapeutics is a leader in RNA interference (RNAi), creating drugs that silence disease-causing genes. This chart shows the average index for the DNA technologies segment. It allows you to assess how Silence Therapeutics' advanced platform performs compared to the sector average across a range of factors.
The AKIM Index for the overall market
Silence Therapeutics is a leader in developing miRNA (RNA interference)-based drugs that silence disease genes. They focus on cardiovascular risks. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific success story with a proven platform compares to overall economic trends.
